ArticleBiochemistry and biophysics reports2026
Bioanalytical methods for quantification of Bevacizumab in human serum: ELISA versus MSD.
Article in Biochemistry and biophysics reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bevacizumab (BVZ) is an anti-vascular Endothelial Growth Factor-A monoclonal antibody (mAb) widely used in oncology and ophthalmology indications globally. Accurate quantification of mAbs in biological fluids is an essential prerequisite for determining pharmacokinetic (PK) parameters to assess the relationship between drug exposure and response. We developed and evaluated PK assays for BVZ in human serum using enzyme-linked immunosorbent assays (ELISA) and Meso Scale Discovery (MSD) immunoassay platforms to assess sensitivity and performance. The ELISA method, employing a Streptavidin-Biotin detection system with anti-idiotypic antibodies, demonstrated five times greater sensitivity than the conventional horseradish peroxidase-based ELISA format. The validated PK bridging ELISA achieved a quantification range of 10-220 ng/mL, extendable to 5000 ng/mL via dilution. In contrast, the MSD assay utilized electrochemiluminescence detection with Sulfo Tag labeling, offering a 20-fold higher sensitivity and detecting BVZ at concentrations as low as 500 pg/mL. This parallel evaluation concluded that ELISA is suitable for routine PK analysis due to its robustness and cost-efficiency. At the same time, MSD is advantageous for detecting BVZ at low concentrations in early-phase clinical trials and ophthalmic applications where serum levels are minimal.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.